Two-photon luminescence imaging of cancer cells using molecularly targeted gold nanorods

Nano Letters

Volumn 7, Issue 4, 2007, Pages 941-945

  Durr, Nicholas J ^a   Larson, Timothy ^a   Smith, Danielle K ^a   Korgel, Brian A ^a   Sokolov, Konstantin ^a,b   Ben Yakar, Adela ^a  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOFLUORESCENCE; CANCER CELLS; EMISSION INTENSITY; TWO-PHOTON LUMINESCENCE (TPL) IMAGING;

BIOCOMPATIBILITY; GOLD; MEDICAL IMAGING; NANORODS; ONCOLOGY; PHOTOLUMINESCENCE;

CELL CULTURE;

COLLOIDAL GOLD; CONTRAST MEDIUM; DIAGNOSTIC AGENT; NANOTUBE;

ARTICLE; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; IMAGE ENHANCEMENT; LUMINESCENCE; MATERIALS TESTING; METHODOLOGY; MULTIPHOTON MICROSCOPY; NANOTECHNOLOGY; PARTICLE SIZE; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; ULTRASTRUCTURE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; GOLD COLLOID; HUMANS; IMAGE ENHANCEMENT; LUMINESCENT MEASUREMENTS; MATERIALS TESTING; MICROSCOPY, FLUORESCENCE, MULTIPHOTON; NANOTECHNOLOGY; NANOTUBES; PARTICLE SIZE;

EID: 34248225277     PISSN: 15306984     EISSN: None     Source Type: Journal    
DOI: 10.1021/nl062962v     Document Type: Article

References (30)

1. Konig, K.; Riemann, I. J. Biomed. Opt. 2003, 8, 432-439.
2. Masters, B. R.; So, P. T.; Gratton, E. Ann. N. Y. Acad. Sci. 1998, 838, 58-67.
3. Zipfel, W. R.; Williams, R. M.; Christie, R.; Nikitin, A. Y.; Hyman, B. T.; Webb, W. W. Proc. Ntal. Acad. Sci. U.S.A. 2003, 100, 7075-7080.
4. Skala, M. C.; Squirrell, J. M.; Vrotsos, K. M.; Eickhoff, J. C.; Gendron-Fitzpatrick, A.; Eliceiri, K. W.; Ramanujam, N. Cancer Res. 2005, 65, 1180-1186.
5. Albota, M.; Beljonne, D.; Bredas, J. L.; Ehrlich, J. E.; Fu, J. Y.; Heikal, A. A.; Hess, S. E.; Kogej, T.; Levin, M. D.; Marder, S. R.; McCord-Maughon, D.; Perry, J. W.; Rockel, H.; Rumi, M.; Subramaniam, G.; Webb, W. W.; Wu, X. L.; Xu, C. Science 1998, 281, 1653-1656.
6. Larson, D. R.; Zipfel, W. R.; Williams, R. M.; Clark, S. W.; Bruchez, M. P.; Wise, F. W.; Webb, W. W. Science 2003, 300, 1434-1436.
7. Farrer, R. A.; Butterfield, F. L.; Chen, V. W.; Fourkas, J. T. Nano Lett. 2005, 5, 1139-1142.
8. Sonnichsen, C.; Alivisatos, A. P. Nano Lett 2005, 5, 301-304.
9. Wang, H.; Huff, T. B.; Zweifel, D. A.; He, W.; Low, P. S.; Wei, A.; Cheng, J. X. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 15752-15756.
10. Yelin, D.; Oron, D.; Thiberge, S.; Moses, E.; Silberberg, Y. Opt. Express 2003, 11, 1385-1391.
11. Zipfel, W. R.; Williams, R. M.; Webb, W. W. Nat. Biotechnol. 2003, 21, 1369-1377.
12. Abrams, M. J.; Murrer, B. A. Science 1993, 261, 725-730.
13. Mooradian, A. Phys. Rev. Lett. 1969, 22, 185-187.
14. Boyd, G. T.; Yu, Z. H.; Shen, Y. R. Phys. Rev. B: Condens. Matter 1986, 33, 7923-7936.
15. Imura, K.; Nagahara, T.; Okamoto, H. J. Phys. Chem. B 2005, 109, 13214-13220.
16. Mohamed, M. B.; Volkov, V.; Link, S.; El-Sayed, M. A. Chem. Phys. Lett. 2000, 317, 517-523.
17. Sonnichsen, C.; Franzl, T.; Wilk, T.; von Plessen, G.; Feldmann, J.; Wilson, O.; Mulvaney, P. Phys. Rev. Lett. 2002, 88, 077402.
18. Bouhelier, A.; Beversluis, M. R.; Novotny, L. Appl. Phys. Lett. 2003, 83, 5041-5043.
19. Huang, X.; El-Sayed, I. H.; Qian, W.; El-Sayed, M. A. J. Am. Chem. Soc. 2006, 128, 2115-2120.
20. Guild, J. B.; Xu, C.; Webb, W. W. Appl. Opt. 1997, 36, 397-401.
21. Gou, L. F.; Murphy, C. J. Chem. Mater. 2005, 17, 3668-3672.
22. Jana, N. R.; Gearheart, L.; Murphy, C. J. J. Phys. Chem. B 2001. 105, 4065-4067.
23. Nikoobakht, B.; El-Sayed, M. A. Chem. Mater. 2003, 75, 1957-1962.
24. The CTAB source was found to be critical for success in the gold nanorod synthesis. For nanorods to form using the published procedures, we found it necessary to use lower purity CTAB. CTAB from both Fluka (96% purity) and MP Biomedical (98% purity) gave Au nanorods. We could not make Au nanorods using CTAB obtained from the following manufacturers: Acros (99% purity). Aldrich (∼100% purity), and Sigma (99% purity). We attribute this difference to the purity in the CTAB. However, we currently do not know what the impurity is or why it is important, only that it dramatically affects the product, and the only way we could reproduce gold nanorod syntheses reported in the literature was to use the CTAB of lower purity from either Fluka or MP Biomedical.
25. Liu, M. Z.; Guyot-Sionnest, P. J. Phys. Chem. B 2005, 109, 22192-22200.
26. Murphy, C. J.; San, T. K.; Gole, A. M.; Orendorff, C. J.; Gao, J. X.; Gou, L.; Hunyadi, S. E.; Li, T. J. Phys. Chem. B 2005, 109, 13857-13870.
27. El-Sayed, I. H.; Huang, X.; El-Sayed, M. A. Nano Lett. 2005, 5, 829-834.
28. Sokolov, K.; Folien, M.; Aaron, J.; Pavlova, I.; Malpica, A.; Lotan, R.; Richards-Kortum, R. Cancer Res. 2003, 63, 1999-2004.
29. Barnes, C. J.; Rakesh, K. Biology of the Epidermal Growth Factor Receptor Family. Springer; New York, 2004; Vol. 119.
30. Schlessinger, J. Cell 2000, 103, 211-225.